Method of determining dihydropyrimidine dehydrogenase gene expression
View Patent ↗The present invention relates to prognostic methods which are useful in medicine, particularly cancer chemotherapy. The object of the invention to provide a method for assessing Dihydropyrimidine dehydrogenase (DPD) expression levels in tissues and prognosticate the probable resistance of a patient's tumor to treatment with 5-FU based therapies by examination of the amount of DPD mRNA in a patient's tumor cells and comparing it to a predetermined threshold expression level. More specifically, the invention provides to oligonucleotide primer pairs DPD3A and DPD3B and methods comprising their use for detecting levels of Dihydropyrimidine dehydrogenase (DPD) mRNA.
1. A method for determining a 5-Fluorouracil-based chemotherapeutic regimen for treating a tumor in patient comprising:
(a) obtaining a tumor sample from the patient;
(b) fixing at least a portion of said tumor sample in paraffin to achieve a fixed and paraffin embedded (FPE) tumor tissue sample,
(c) isolating mRNA from said FPE tumor tissue sample;
(d) subjecting the mRNA isolated from said FPE tumor tissue to amplification using a pair of oligonucleotide primers SEQ ID NO: 1 and SEQ ID NO: 2 to obtain an amplified sample,
(e) determining the amount of Dihydropyrimidine Dehydrogenase (DPD) mRNA in the amplified sample;
(f) comparing the amount of Dihydropyrimidine Dehydrogenase (DPD) mRNA in the amplified sample with a predetermined threshold level for DPD expression;
(g) determining a 5-Fluorouracil-based chemotherapeutic regimen for said patient based on the difference in amount of DPD mRNA in the amplified sample and the threshold level for DPD gene expression.
2. The method of claim 1 , wherein said predetermined threshold level of DPD gene expression is about 2.0 to about 2.5 times that of an internal control gene expression level.
3. The method of claim 1 or 2 , wherein said internal control gene is b-actin.
4. The method of claim 1 or 2 , wherein the mRNA is isolated in the presence of an effective amount of chaotropic agent.
5. A method for determining a 5-Fluorouracil-based chemotherapeutic regimen for treating a tumor in a patient comprising:
(a) obtaining a tumor sample from the tumor;
(b) fixing at least a portion of said tumor sample in paraffin to achieve a fixed and paraffin embedded (FPE) tumor tissue sample,
(c) isolating mRNA from said FPE tumor tissue sample;
(d) subjecting the mRNA isolated from said FPE tumor tissue to amplification using a pair of oligonucleotide primers SEQ ID NO: 7 and SEQ ID NO: 8 to obtain an amplified sample;
(e) determining the amount of Dihydropyrimidine Dehydrogenase (DPD) mRNA in the amplified sample;
(f) comparing the amount of Dihydropyrimidine Dehydrogenase (DPD) mRNA in the amplified sample with a predetermined threshold level for DPD expression;
(g) determining a 5-Fluorouracil-based chemotherapeutic regimen for said patient based on the difference in amount of DPD mRNA in the amplified sample and the threshold level for DPD gene expression.
6. The method of claim 5 , wherein said predetermined threshold level of DPD gene expression is about 2.0 to about 2.5 times that of an internal control gene expression level.
7. The method of claim 5 or 6 , wherein said internal control gene is b-actin.
8. A method for determining a 5-Fluorouracil-based chemotherapeutic regimen for treating a tumor in patient comprising:
(a) obtaining a tumor sample from the patient, and wherein said tumor sample is fixed and paraffin embedded (FPE);
(b) isolating mRNA from said FPE tumor tissue sample, wherein said tumor sample is heated to a temperature in the range of 50 to 100° C.;
(c) subjecting the mRNA isolated from said FPE tumor tissue to amplification using a pair of oligonucleotide primers SEQ ID NO: 1 to obtain an amplified sample,
(d) determining the amount of Dihydropyrimidine Dehydrogenase (DPD) mRNA in the amplified sample;
(e) comparing the amount of Dihydropyrimidine Dehydrogenase (DPD) mRNA in the amplified sample with a predetermined threshold level for DPD expression;
(f) determining a 5-Fluorouracil-based chemotherapeutic regimen for said patient based on the difference in amount of DPD mRNA in the amplified sample and the threshold level for DPD gene expression.
9. The method of claim 8 , wherein said predetermined threshold level of DPD gene expression is about 2.0 to about 2.5 times that of an internal control gene expression level.
10. The method of claim 8 or 9 , wherein said internal control gene is b-actin.
11. The method of claim 8 or 9 , wherein the heating is in the presence of an effective amount of chaotropic agent.
12. A method for determining a 5-Fluorouracil-based chemotherapeutic regimen for treating a tumor in patient comprising:
(a) obtaining a tumor tissue sample from the patient, and wherein said tumor tissue sample is fixed and paraffin embedded (FPE);
(b) isolating mRNA from said FPE tumor tissue sample, wherein said tumor sample is heated to a temperature in the range of 50 to 100° C.;
(c) subjecting the mRNA isolated from said FPE tumor tissue sample to amplification using a pair of oligonucleotide primers SEQ ID NO: 7 and SEQ ID NO: 8 to obtain an amplified sample;
(d) determining the amount of Dihydropyrimidine Dehydrogenase (DPD) mRNA in the amplified sample;
(e) comparing the amount of Dihydropyrimidine Dehydrogenase (DPD) mRNA in the amplified sample with a predetermined threshold level for DPD expression;
(f) determining a 5-Fluorouracil-based chemotherapeutic regimen for said patient based on the difference in amount of DPD mRNA in the amplified sample and the threshold level for DPD gene expression.
13. The method of claim 12 , wherein said internal control gene is b-actin.
14. The method of claim 8 , wherein the heating is in the presence of an effective amount of chaotropic agent.